MFG
CLSD

Merit Financial Group’s Clearside Biomedical CLSD Stock Holding History

Merit Financial Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-733
Closed -$12.3K – 652
2022
Q4 		$12.3K Hold
733
– – ﹤0.01% 683
2022
Q3 		$12K Hold
733
– – ﹤0.01% 566
2022
Q2 		$16K Buy
+733
New +$17.8K ﹤0.01% 565

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Merit Financial Group's CLSD Position: Q1 2023 in Review

Merit Financial Group sold out of Clearside Biomedical (CLSD) in Q1 2023, closing a stake of 733 shares — an estimated $12.3K sold.

Merit Financial Group first reported a position in CLSD in Q2 2022 and held it in 3 quarters. The position peaked at $16K in Q2 2022. 50 funds tracked by Wall St. Rank hold CLSD as of Q1 2023.

  • Merit Financial Group reported no remaining Clearside Biomedical position as of Q1 2023 after selling out during the quarter.
  • Merit Financial Group sold 733 Clearside Biomedical shares in Q1 2023, an estimated $12.3K.
  • Merit Financial Group first reported a position in Clearside Biomedical in Q2 2022 and held it in 3 quarters.
  • Merit Financial Group's Clearside Biomedical position peaked at $16K in Q2 2022.
  • 50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2023.

Based on Merit Financial Group's 13F filing for Q1 2023, filed 24 Apr 2023.